Publicaciones en colaboración con investigadores/as de University College London (25)

2024

  1. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx (Nature, (2023), 616, 7957, (525-533), 10.1038/s41586-023-05783-5)

    Nature

  2. Fcγ receptors and immunomodulatory antibodies in cancer

    Nature Reviews Cancer, Vol. 24, Núm. 1, pp. 51-71

  3. MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution

    Nature Genetics

  4. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

    Nature Communications, Vol. 15, Núm. 1

  5. Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models

    Nature Communications , Vol. 15, Núm. 1

  6. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

    Nature Cancer, Vol. 5, Núm. 2, pp. 347-363

2023

  1. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

    Nature, Vol. 616, Núm. 7957, pp. 563-573

  2. Body composition and lung cancer-associated cachexia in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 846-858

  3. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 833-845

  4. Genomic–transcriptomic evolution in lung cancer and metastasis

    Nature, Vol. 616, Núm. 7957, pp. 543-552

  5. Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials

    The oncologist, Vol. 28, Núm. 4, pp. e205-e211

  6. Lung adenocarcinoma promotion by air pollutants

    Nature, Vol. 616, Núm. 7955, pp. 159-167

  7. Protective ileostomy creation after anterior resection of the rectum: Shared decision-making or still subjective?

    Colorectal Disease, Vol. 25, Núm. 4, pp. 647-659

  8. The evolution of lung cancer and impact of subclonal selection in TRACERx

    Nature, Vol. 616, Núm. 7957, pp. 525-533

  9. The evolution of non-small cell lung cancer metastases in TRACERx

    Nature, Vol. 616, Núm. 7957, pp. 534-542

  10. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

    Nature, Vol. 616, Núm. 7957, pp. 553-562

2022

  1. A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer

    Nature Cancer, Vol. 3, Núm. 6, pp. 696-709

  2. Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling

    Nature Cancer, Vol. 3, Núm. 11, pp. 1336-1350

  3. Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling (Nature Cancer, (2022), 3, 11, (1336-1350), 10.1038/s43018-022-00447-1)

    Nature Cancer

  4. Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery

    BJS Open, Vol. 6, Núm. 1